Skip to Content
Pharma Technology
  • Products

    Process


    External Lubrication Tablet dedusting Capsule polishing IPC testing

    Packaging


    Tablet sorting

    Quality Control


    PAT solutionsVisual Inspection
  • Services
  • News
  • About us
  • 0
  • Sign in
  • Contact Us
Pharma Technology
  • 0
    • Products
    • Services
    • News
    • About us
  • Sign in
  • Contact Us

Performances of API fraction predictions

with NIR-SRS and with Transmission FT-NIR:A Comparative Case Study
  • All Blogs
  • Articles
  • Performances of API fraction predictions
  • July 16, 2026 by
    Performances of API fraction predictions
    Pharma Technology
    Zita Kelemen, Freddy Vandenbroucke, Pharma Technology, Belgium

    Yoann Gut, Antoine Raguet, Les Laboratoires Servier, France

    Introduction

    Accurate quantification of active pharmaceutical ingredients (APIs) is a cornerstone of pharmaceutical quality control, ensuring the safety, efficacy, and consistency of drug products. As the industry moves toward faster and more efficient manufacturing processes, there is growing demand for analytical techniques that are non-destructive, rapid, but also reliable. Near-infrared (NIR) spectroscopy has emerged as a key technology in this transition, offering the potential for real-time analysis without compromising sample integrity.

    This study compares the API prediction performance of two NIR-based techniques: transmission Fourier-transform NIR (FT-NIR), a well-established bench-top method, and near-infrared spatially resolved
    spectroscopy (NIR-SRS) implemented in the CUB-X system, a novel approach designed for increased flexibility and higher analytical throughput. By evaluating these methods under varying sample conditions,

    we investigate whether the faster NIR-SRS technique can achieve predictive performance comparable to conventional FT-NIR, while meeting the stringent reliability requirements of pharmaceutical analysis.

    Download the poster

    Methods

    Experimental design

    • Tablets with 25% w/w API
    • 3 hardness levels: 80N - 120N - 160N
    • 5 levels of API content (% LC): 70% - 85% - 100% - 115% - 130%
    • 15 batches x 55 tablets: 825 tablets
    • Multi – day measurements (variability captured)

    Workflow

    • Tablets
    • NIR-SRS | FT-NIR
    • Preprocessing
    • PLS models
    • Validation

    NIR - SRS

    Schematic diagram of NIR – SRS

    Preprocessing: The spectra were preprocessed using standard normal variate (SNV) correction, followed by generalized least squares weighting (GLSW, α = 0.02), and a Savitzky–Golay firstderivative filter (window 15, polynomial order 2).
    Spectral range: 950–1650 nm (10526–6060 cm-1)

    825 tablets x 3 repetitions = 2475 spectra
    • Calibration: 15 tablets/batch (675 spectra)
    • Validation (test): 40 tablets/batch (1800 spectra)
    ​

    FT - NIR

    Schematic diagram of FT – NIR

    Preprocessing: SNV followed by Savitzky–Golay second-derivative filter (window 15, order 2) and a mean center.

    Spectral range: 11650–7050 cm-1 (858–11418 nm)

    825 tablets = 825 spectra
    • Calibration: 15 tablets/batch (225 spectra)
    • Validation (test): 40 tablets/batch (600 spectra)
    ​

    NIR - SRS

    Parameters

    FT - NIR

    Wavelength [nm]

    Measurement unit

    Wavenumber [cm-1]

    900 – 1650 [nm]

    Spectral range

    12800 – 5800 [cm-1]

    3x1 ms

    Acquisition time

    32 scans (16 s)

    Diffuse reflectance

    Mode

    Transmission

    Results

    In the absence of reference measurements, the nominal tablet strength (% LC) was used as the target variable for model development. Spectral preprocessing and multivariate modeling for both systems were performed using PLS_Toolbox (Eigenvector). Given the large number of available validation samples, a basic cross-validation approach was applied for both models (Venetian blinds, 10 splits, 1 sample/blind).

    • Despite the pronounced influence of tablet hardness on the spectral response, predicted values from both techniques closely matched the nominal tablet strength (% LC).
    • While different preprocessing strategies and model parameterizations were required - partly due to software constraints of the FT-NIR bench-top device - comparable predictive performance was obtained.

    NIR - SRS

    ​

    FT - NIR


    ​

    NIR - SRS


    FT - NIR

    0.99

    R²C

    0.99

    1.7

    RMSEC %LC

    1.5

    1.8

    RMSECV %LC

    1.6

    1.7

    RMSEP %LC

    1.7

    4

    LV

    4

    Conclusion

    • Both FT-NIR and NIR-SRS achieved comparable accuracy and robustness in predicting API mass fractions in pharmaceutical tablets.
    • While FT-NIR provided slightly more stable spectra due to controlled conditions, NIR-SRS matched its predictive performance while enabling significantly faster measurements and higher throughput.
    • This makes NIR-SRS well suited for real-time or at-line quality control, reducing analysis time and supporting more efficient pharmaceutical manufacturing.

    Feature

    NIR - SRS

    FT - NIR

    Accuracy

    Excellent

    Excellent

    Speed

    Fast

    Slow

    Throughput

    High

    Limited

    Robustness

    Good

    Good


    in Articles
    # PAT Quality Control R&D Scientific publication
    Share this post
    Tags
    PAT Quality Control R&D Scientific publication
    Our blogs
    • Articles
    • Stories
    • Events
    • Scientific Publications

    Our latest content

    Check out what's new in our company !

    See all
    Your Dynamic Snippet will be displayed here... This message is displayed because you did not provide both a filter and a template to use.
    Pharma Technology logo
    Pharma Technology logo

    Rue Graham Bell 8, B-1402 Thines, Belgium

    • +32 67 70 13 00
    • Contact us
    Follow us
    2026 © Pharmatec. All rights reserv​ed
    Powered by Odoo - The #1 Open Source eCommerce

    Respecting your privacy is our priority.

    Allow the use of cookies from this website on this browser?

    We use cookies to provide improved experience on this website. You can learn more about our cookies and how we use them in our Cookie Policy.

    Allow all cookies
    Only allow essential cookies